LVTX•benzinga•
LAVA Therapeutics Reports Q4 Revenues Of $4.99M, Compared With $353,000 YoY; Company Exits Quarter With Cash & Equivalents Worth $35.015M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 28, 2025 by benzinga